Biggest News Aggregation in the World
📰 Networking Event News

Page 13 - Networking Event News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Networking Event. Real-time updates on events, politics, business and more.

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O

DGAP-News: Vivoryon Therapeutics N.V. / Key word: Study results/Study Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that... | July 31, 2022
San Diego United States University Of California San Diego Ulrich Dauer Manuela Bader Michael Schaeffer

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique Opportunity in AD

Safety data from 181 patients show no on-target toxicity and no clinical signs of ARIATherapeutic dose of 600 mg varoglutamstat given twice daily selected by the Data Safety Monitoring Board is known to
San Diego United States University Of California San Diego Ulrich Dauer Manuela Bader Michael Schaeffer

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): StudyVivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022 (news with additional features)31.07.2022 / 18:05 The issuer is solely responsible for the content of t...
United States San Diego Cynthia Lemere Manuela Bader Michael Schaeffer Alzheimer Association International Conference

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showi

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Study results/StudyVivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O (news with additional features)31.07.2022 /...
San Diego United States University Of California San Diego Ulrich Dauer Manuela Bader Michael Schaeffer

DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Study results/Study Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat
San Diego United States University Of California San Diego Noord Holland Ulrich Dauer Halle Saale

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science